{"denoms":[{"counts":[{"groupId":"OG000","value":"0"}],"units":"Participants"}],"description":"Improvement in progression free survival (PFS)in locally advanced stage III and IV head and neck cancer patients with sequential (ICT) followed by Concurrent chemo-radiotherapy (CR) using monoclonal antibody Cetuximab as compared to historical controls.","groups":[{"description":"Single arm Phase II Study Induction Chemo then Concurrent Chemoradiotherapy with Cetuximab in Locally Advanced Head and Neck Squamous Cell Cancer\n\nCetuximab: Single arm phase II study of chemotherapy","id":"OG000","title":"Single Arm"}],"populationDescription":"The Principal Investigator left the institution. Despite exhausting all efforts to contact the Responsible Party and study team members to retrieve the collected data, or to have them enter the data, efforts were unsuccessful, and no data are available to be reported","reportingStatus":"POSTED","timeFrame":"Analysis at Week 26","title":"Progression Free Survival","type":"SECONDARY"}